News | January 03, 2011

Axxent controller


January 3, 2011 — iCAD Inc., a provider of advanced image analysis and workflow solutions for the early identification of cancer, has signed a definitive agreement to acquire Xoft Inc., developer of the Axxent eBx electronic brachytherapy system.

“The acquisition of Xoft will transform iCAD from a company focused on image analysis for the early detection of cancers to a broader player in the oncology market. We believe that early detection in combination with earlier targeted intervention will provide patients and care providers with the best tools available to achieve better clinical outcomes,” said Ken Ferry, president and CEO of iCAD.

For more information: www.icadmed.com, www.xoftinc.com

Certain statements contained in this News Release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks relating to the Company’s proposed acquisition of Xoft including, the expected benefits of the acquisition may not be achieved in a timely manner, or at all; the Xoft business operations may not be successfully integrated with iCAD’s following the closing and iCAD may be unable to achieve the expected synergies, business and strategic objectives following the transaction. In addition, there can be no assurance that the transaction will occur by the end of 2010, or at all  and other risks detailed in the Company’s filings with the Securities and Exchange Commission. The words “believe”, “demonstrate”, “intend”, “expect”, “estimate”, “anticipate”, “likely”, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release.


Related Content

News | ASTRO

Sept. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has named Siemens Healthineers the inaugural ...

Time September 29, 2026
arrow
News | Proton Therapy

Sept. 28, 2026 — Penn Medicine and Ion Beam Applications (IBA) have formed Noventra Oncology Alliance, a new joint ...

Time September 28, 2026
arrow
News | ASTRO

Sept. 22, 2026 — Leading experts in radiation therapy from the Abramson Cancer Center (ACC) of the University of ...

Time September 24, 2026
arrow
News | Computed Tomography (CT)

Sept. 17, 2026 — Royal Philips and Southwest Mississippi Regional Medical Center (SMRMC), which serves as the hub of ...

Time September 24, 2026
arrow
News | ASTRO

Sept.16, 2026 — For appropriately selected patients with muscle-invasive bladder cancer, preserving the bladder can be a ...

Time September 17, 2026
arrow
News | Radiology Education

Sept. 16, 2026 — As urgent care centers and outpatient healthcare facilities expand their use of diagnostic imaging, the ...

Time September 17, 2026
arrow
News | PET Imaging

Sept. 10, 2026 — Siemens Healthineers Molecular Imaging has completed a $43.6 million construction and renovation ...

Time September 14, 2026
arrow
News | Radiology Imaging

Sept. 1, 2026 — Leo Cancer Care and GE HealthCare have announced that the two companies intend to work together on GE ...

Time September 11, 2026
arrow
News | ASTRO

Sept. 9, 2026 — The 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, will take place Sept. 26 to 30 ...

Time September 11, 2026
arrow
News | Breast Imaging

Sept. 10, 2026 — An artificial intelligence model that analyzes women's past and recent annual 3D mammograms is more ...

Time September 10, 2026
arrow
Subscribe Now